Literature DB >> 1569771

Preoperative chemotherapy and radiotherapy for esophageal carcinoma.

K S Naunheim1, P Petruska, T S Roy, C H Andrus, F E Johnson, J M Schlueter, A E Baue.   

Abstract

From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p less than 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569771

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

1.  Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients.

Authors:  Torben Glatz; Goran Marjanovic; Birte Kulemann; Olivia Sick; Ulrich Theodor Hopt; Jens Hoeppner
Journal:  Langenbecks Arch Surg       Date:  2017-01-12       Impact factor: 3.445

Review 2.  Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.

Authors:  Hiroshi Okumura; Yasuto Uchikado; Tetsuro Setoyama; Masataka Matsumoto; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

3.  Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy.

Authors:  Frank Makowiec; Peter Baier; Birte Kulemann; Goran Marjanovic; Peter Bronsert; Katja Zirlik; Michael Henke; Ulrich Theodor Hopt; Jens Hoeppner
Journal:  J Gastrointest Surg       Date:  2013-05-02       Impact factor: 3.452

4.  [Surgical treatment of esophageal cancer : Evolution of management and prognosis over the last 3 decades].

Authors:  T Glatz; G Marjanovic; K Zirlik; T Brunner; U T Hopt; F Makowiec; J Hoeppner
Journal:  Chirurg       Date:  2015-07       Impact factor: 0.955

5.  Pulmonary Complications due to Esophagectomy.

Authors:  Abulfazl Shirinzadeh; Yashar Talebi
Journal:  J Cardiovasc Thorac Res       Date:  2011-08-20

Review 6.  Transhiatal esophagectomy for treatment of benign and malignant esophageal disease.

Authors:  M B Orringer; B Marshall; M D Iannettoni
Journal:  World J Surg       Date:  2001-02       Impact factor: 3.352

Review 7.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 8.  Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.

Authors:  Johannes Zacherl; Andreas Sendler; Hubert J Stein; Katja Ott; Marcus Feith; Raimund Jakesz; J Rüdiger Siewert; Ulrich Fink
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

9.  Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer.

Authors:  H Yamanaka; T Motohiro; T Michiura; A Asai; T Mori; K Hioki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-10

10.  Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.

Authors:  M K Ferguson; L B Reeder; P C Hoffman; D J Haraf; L C Drinkard; E E Vokes
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.